1	4	_	_	_	_	_	_	_	_
2	.	_	_	_	_	_	_	_	_


1	Discussion	_	_	_	_	_	_	_	_


1	Recognizing	_	_	_	_	_	_	_	_
2	patients	_	_	_	_	_	_	_	_
3	with	_	_	_	_	_	_	_	_
4	monogenic	_	_	_	_	_	_	_	_


1	AIDs	_	_	_	_	_	_	_	_
2	is	_	_	_	_	_	_	_	_
3	difficult	_	_	_	_	_	_	_	_
4	because	_	_	_	_	_	_	_	_
5	their	_	_	_	_	_	_	_	_
6	clinical	_	_	_	_	_	_	_	_
7	spectrum	_	_	_	_	_	_	_	_
8	may	_	_	_	_	_	_	_	_
9	range	_	_	_	_	_	_	_	_
10	from	_	_	_	_	_	_	_	_
11	very	_	_	_	_	_	_	_	_
12	mild	_	_	_	_	_	_	_	_
13	inflammatory	_	_	_	_	_	_	_	_
14	episodes	_	_	_	_	_	_	_	_
15	to	_	_	_	_	_	_	_	_
16	severe	_	_	_	_	_	_	_	_
17	chronic	_	_	_	_	_	_	_	_
18	disease	_	_	_	_	_	_	_	_
19	.	_	_	_	_	_	_	_	_


1	Moreover	_	_	_	_	_	_	_	_
2	,	_	_	_	_	_	_	_	_
3	the	_	_	_	_	_	_	_	_
4	disease	_	_	_	_	_	_	_	_
5	features	_	_	_	_	_	_	_	_
6	significantly	_	_	_	_	_	_	_	_
7	overlap	_	_	_	_	_	_	_	_
8	.	_	_	_	_	_	_	_	_


1	Our	_	_	_	_	_	_	_	_
2	targeted	_	_	_	_	_	_	_	_
3	NGS	_	_	_	_	_	_	_	_
4	approach	_	_	_	_	_	_	_	_
5	resulted	_	_	_	_	_	_	_	_
6	in	_	_	_	_	_	_	_	_
7	genetic	_	_	_	_	_	_	_	_
8	confirmation	_	_	_	_	_	_	_	_
9	in	_	_	_	_	_	_	_	_
10	a	_	_	_	_	_	_	_	_
11	relatively	_	_	_	_	_	_	_	_
12	small	_	_	_	_	_	_	_	_
13	proportion	_	_	_	_	_	_	_	_
14	(	_	_	_	_	_	_	_	_
15	7	_	_	_	_	_	_	_	_
16	%	_	_	_	_	_	_	_	_
17	)	_	_	_	_	_	_	_	_
18	of	_	_	_	_	_	_	_	_
19	patients	_	_	_	_	_	_	_	_
20	.	_	_	_	_	_	_	_	_


1	This	_	_	_	_	_	_	_	_
2	finding	_	_	_	_	_	_	_	_
3	is	_	_	_	_	_	_	_	_
4	consistent	_	_	_	_	_	_	_	_
5	with	_	_	_	_	_	_	_	_
6	two	_	_	_	_	_	_	_	_
7	2019	_	_	_	_	_	_	_	_
8	reports	_	_	_	_	_	_	_	_
9	by	_	_	_	_	_	_	_	_
10	Karacan	_	_	_	_	_	_	_	_
11	et	_	_	_	_	_	_	_	_
12	al.	_	_	_	_	_	_	_	_
13	and	_	_	_	_	_	_	_	_
14	Papa	_	_	_	_	_	_	_	_
15	et	_	_	_	_	_	_	_	_
16	al.	_	_	_	_	_	_	_	_
17	,	_	_	_	_	_	_	_	_
18	who	_	_	_	_	_	_	_	_
19	used	_	_	_	_	_	_	_	_
20	recent	_	_	_	_	_	_	_	_
21	guidelines	_	_	_	_	_	_	_	_
22	for	_	_	_	_	_	_	_	_
23	the	_	_	_	_	_	_	_	_
24	definition	_	_	_	_	_	_	_	_
25	of	_	_	_	_	_	_	_	_
26	positive	_	_	_	_	_	_	_	_
27	diagnosis	_	_	_	_	_	_	_	_
28	as	_	_	_	_	_	_	_	_
29	we	_	_	_	_	_	_	_	_
30	did	_	_	_	_	_	_	_	_
31	.	_	_	_	_	_	_	_	_


1	Three	_	_	_	_	_	_	_	_
2	previous	_	_	_	_	_	_	_	_
3	studies	_	_	_	_	_	_	_	_
4	using	_	_	_	_	_	_	_	_
5	a	_	_	_	_	_	_	_	_
6	broader	_	_	_	_	_	_	_	_
7	definition	_	_	_	_	_	_	_	_
8	claimed	_	_	_	_	_	_	_	_
9	19	_	_	_	_	_	_	_	_
10	%	_	_	_	_	_	_	_	_
11	,	_	_	_	_	_	_	_	_
12	20	_	_	_	_	_	_	_	_
13	%	_	_	_	_	_	_	_	_
14	,	_	_	_	_	_	_	_	_
15	and	_	_	_	_	_	_	_	_
16	22	_	_	_	_	_	_	_	_
17	%	_	_	_	_	_	_	_	_
18	diagnostic	_	_	_	_	_	_	_	_
19	yield	_	_	_	_	_	_	_	_
20	.	_	_	_	_	_	_	_	_


1	In	_	_	_	_	_	_	_	_
2	those	_	_	_	_	_	_	_	_
3	reports	_	_	_	_	_	_	_	_
4	,	_	_	_	_	_	_	_	_
5	for	_	_	_	_	_	_	_	_
6	example	_	_	_	_	_	_	_	_
7	,	_	_	_	_	_	_	_	_
8	frequent	_	_	_	_	_	_	_	_
9	variants	_	_	_	_	_	_	_	_
10	,	_	_	_	_	_	_	_	_
11	such	_	_	_	_	_	_	_	_
12	as	_	_	_	_	_	_	_	_
13	p.	_	_	_	_	_	_	_	_
14	(	_	_	_	_	_	_	_	_
15	Glu148Gln	_	_	_	_	_	_	_	_
16	)	_	_	_	_	_	_	_	_
17	(	_	_	_	_	_	_	_	_
18	MEFV	_	_	_	_	_	_	_	_
19	)	_	_	_	_	_	_	_	_
20	,	_	_	_	_	_	_	_	_
21	p.	_	_	_	_	_	_	_	_
22	(	_	_	_	_	_	_	_	_
23	Arg121Gln	_	_	_	_	_	_	_	_
24	)	_	_	_	_	_	_	_	_
25	(	_	_	_	_	_	_	_	_
26	TNFRSF1A	_	_	_	_	_	_	_	_
27	)	_	_	_	_	_	_	_	_
28	,	_	_	_	_	_	_	_	_
29	or	_	_	_	_	_	_	_	_
30	p.	_	_	_	_	_	_	_	_
31	(	_	_	_	_	_	_	_	_
32	Val198Met	_	_	_	_	_	_	_	_
33	)	_	_	_	_	_	_	_	_
34	(	_	_	_	_	_	_	_	_
35	NLRP3	_	_	_	_	_	_	_	_
36	)	_	_	_	_	_	_	_	_
37	,	_	_	_	_	_	_	_	_
38	and	_	_	_	_	_	_	_	_
39	all	_	_	_	_	_	_	_	_
40	known	_	_	_	_	_	_	_	_
41	susceptibility	_	_	_	_	_	_	_	_
42	factors	_	_	_	_	_	_	_	_
43	for	_	_	_	_	_	_	_	_
44	inflammation	_	_	_	_	_	_	_	_
45	were	_	_	_	_	_	_	_	_
46	considered	_	_	_	_	_	_	_	_
47	consistent	_	_	_	_	_	_	_	_
48	with	_	_	_	_	_	_	_	_
49	the	_	_	_	_	_	_	_	_
50	diagnosis	_	_	_	_	_	_	_	_
51	.	_	_	_	_	_	_	_	_


1	Moreover	_	_	_	_	_	_	_	_
2	,	_	_	_	_	_	_	_	_
3	our	_	_	_	_	_	_	_	_
4	definition	_	_	_	_	_	_	_	_
5	was	_	_	_	_	_	_	_	_
6	more	_	_	_	_	_	_	_	_
7	stringent	_	_	_	_	_	_	_	_
8	than	_	_	_	_	_	_	_	_
9	these	_	_	_	_	_	_	_	_
10	four	_	_	_	_	_	_	_	_
11	previous	_	_	_	_	_	_	_	_
12	studies	_	_	_	_	_	_	_	_
13	because	_	_	_	_	_	_	_	_
14	we	_	_	_	_	_	_	_	_
15	considered	_	_	_	_	_	_	_	_
16	that	_	_	_	_	_	_	_	_
17	we	_	_	_	_	_	_	_	_
18	could	_	_	_	_	_	_	_	_
19	not	_	_	_	_	_	_	_	_
20	conclude	_	_	_	_	_	_	_	_
21	on	_	_	_	_	_	_	_	_
22	the	_	_	_	_	_	_	_	_
23	diagnosis	_	_	_	_	_	_	_	_
24	when	_	_	_	_	_	_	_	_
25	the	_	_	_	_	_	_	_	_
26	parent	_	_	_	_	_	_	_	_
27	â€™s	_	_	_	_	_	_	_	_
28	DNA	_	_	_	_	_	_	_	_
29	was	_	_	_	_	_	_	_	_
30	lacking	_	_	_	_	_	_	_	_
31	segregation	_	_	_	_	_	_	_	_
32	analyses	_	_	_	_	_	_	_	_
33	of	_	_	_	_	_	_	_	_
34	heterozygous	_	_	_	_	_	_	_	_
35	rare	_	_	_	_	_	_	_	_
36	VOUS	_	_	_	_	_	_	_	_
37	.	_	_	_	_	_	_	_	_


1	The	_	_	_	_	_	_	_	_
2	low	_	_	_	_	_	_	_	_
3	performance	_	_	_	_	_	_	_	_
4	of	_	_	_	_	_	_	_	_
5	the	_	_	_	_	_	_	_	_
6	AIDs	_	_	_	_	_	_	_	_
7	panel	_	_	_	_	_	_	_	_
8	might	_	_	_	_	_	_	_	_
9	also	_	_	_	_	_	_	_	_
10	be	_	_	_	_	_	_	_	_
11	explained	_	_	_	_	_	_	_	_
12	by	_	_	_	_	_	_	_	_
13	our	_	_	_	_	_	_	_	_
14	study	_	_	_	_	_	_	_	_
15	design	_	_	_	_	_	_	_	_
16	that	_	_	_	_	_	_	_	_
17	did	_	_	_	_	_	_	_	_
18	not	_	_	_	_	_	_	_	_
19	include	_	_	_	_	_	_	_	_
20	most	_	_	_	_	_	_	_	_
21	of	_	_	_	_	_	_	_	_
22	the	_	_	_	_	_	_	_	_
23	patients	_	_	_	_	_	_	_	_
24	with	_	_	_	_	_	_	_	_
25	features	_	_	_	_	_	_	_	_
26	of	_	_	_	_	_	_	_	_
27	FMF	_	_	_	_	_	_	_	_
28	,	_	_	_	_	_	_	_	_
29	MKD	_	_	_	_	_	_	_	_
30	,	_	_	_	_	_	_	_	_
31	and	_	_	_	_	_	_	_	_
32	DADA2	_	_	_	_	_	_	_	_
33	because	_	_	_	_	_	_	_	_
34	they	_	_	_	_	_	_	_	_
35	were	_	_	_	_	_	_	_	_
36	screened	_	_	_	_	_	_	_	_
37	by	_	_	_	_	_	_	_	_
38	Sanger	_	_	_	_	_	_	_	_
39	sequencing	_	_	_	_	_	_	_	_
40	.	_	_	_	_	_	_	_	_


1	Still	_	_	_	_	_	_	_	_
2	,	_	_	_	_	_	_	_	_
3	the	_	_	_	_	_	_	_	_
4	genes	_	_	_	_	_	_	_	_
5	MEFV	_	_	_	_	_	_	_	_
6	,	_	_	_	_	_	_	_	_
7	MVK	_	_	_	_	_	_	_	_
8	,	_	_	_	_	_	_	_	_
9	and	_	_	_	_	_	_	_	_
10	ADA2	_	_	_	_	_	_	_	_
11	remained	_	_	_	_	_	_	_	_
12	among	_	_	_	_	_	_	_	_
13	the	_	_	_	_	_	_	_	_
14	four	_	_	_	_	_	_	_	_
15	most	_	_	_	_	_	_	_	_
16	frequently	_	_	_	_	_	_	_	_
17	involved	_	_	_	_	_	_	_	_
18	in	_	_	_	_	_	_	_	_
19	the	_	_	_	_	_	_	_	_
20	conclusive	_	_	_	_	_	_	_	_
21	diagnoses	_	_	_	_	_	_	_	_
22	of	_	_	_	_	_	_	_	_
23	our	_	_	_	_	_	_	_	_
24	study	_	_	_	_	_	_	_	_
25	.	_	_	_	_	_	_	_	_


1	This	_	_	_	_	_	_	_	_
2	observation	_	_	_	_	_	_	_	_
3	possibly	_	_	_	_	_	_	_	_
4	stems	_	_	_	_	_	_	_	_
5	from	_	_	_	_	_	_	_	_
6	a	_	_	_	_	_	_	_	_
7	better	_	_	_	_	_	_	_	_
8	detection	_	_	_	_	_	_	_	_
9	by	_	_	_	_	_	_	_	_
10	NGS	_	_	_	_	_	_	_	_
11	of	_	_	_	_	_	_	_	_
12	the	_	_	_	_	_	_	_	_
13	new	_	_	_	_	_	_	_	_
14	molecular	_	_	_	_	_	_	_	_
15	mechanisms	_	_	_	_	_	_	_	_
16	involved	_	_	_	_	_	_	_	_
17	in	_	_	_	_	_	_	_	_
18	AIDs	_	_	_	_	_	_	_	_
19	(	_	_	_	_	_	_	_	_
20	mosaicism	_	_	_	_	_	_	_	_
21	,	_	_	_	_	_	_	_	_
22	CNVs	_	_	_	_	_	_	_	_
23	)	_	_	_	_	_	_	_	_
24	and	_	_	_	_	_	_	_	_
25	better	_	_	_	_	_	_	_	_
26	information	_	_	_	_	_	_	_	_
27	on	_	_	_	_	_	_	_	_
28	these	_	_	_	_	_	_	_	_
29	three	_	_	_	_	_	_	_	_
30	diseases	_	_	_	_	_	_	_	_
31	because	_	_	_	_	_	_	_	_
32	they	_	_	_	_	_	_	_	_
33	are	_	_	_	_	_	_	_	_
34	among	_	_	_	_	_	_	_	_
35	the	_	_	_	_	_	_	_	_
36	best-described	_	_	_	_	_	_	_	_
37	AIDs	_	_	_	_	_	_	_	_
38	.	_	_	_	_	_	_	_	_


1	In	_	_	_	_	_	_	_	_
2	addition	_	_	_	_	_	_	_	_
3	,	_	_	_	_	_	_	_	_
4	FMF	_	_	_	_	_	_	_	_
5	is	_	_	_	_	_	_	_	_
6	now	_	_	_	_	_	_	_	_
7	recognized	_	_	_	_	_	_	_	_
8	as	_	_	_	_	_	_	_	_
9	a	_	_	_	_	_	_	_	_
10	disease	_	_	_	_	_	_	_	_
11	caused	_	_	_	_	_	_	_	_
12	by	_	_	_	_	_	_	_	_
13	gain-of-function	_	_	_	_	_	_	_	_
14	variants	_	_	_	_	_	_	_	_
15	with	_	_	_	_	_	_	_	_
16	a	_	_	_	_	_	_	_	_
17	dosage	_	_	_	_	_	_	_	_
18	effect	_	_	_	_	_	_	_	_
19	rather	_	_	_	_	_	_	_	_
20	than	_	_	_	_	_	_	_	_
21	a	_	_	_	_	_	_	_	_
22	purely	_	_	_	_	_	_	_	_
23	recessive	_	_	_	_	_	_	_	_
24	condition	_	_	_	_	_	_	_	_
25	.	_	_	_	_	_	_	_	_


1	For	_	_	_	_	_	_	_	_
2	one-third	_	_	_	_	_	_	_	_
3	of	_	_	_	_	_	_	_	_
4	the	_	_	_	_	_	_	_	_
5	patients	_	_	_	_	_	_	_	_
6	with	_	_	_	_	_	_	_	_
7	one	_	_	_	_	_	_	_	_
8	heterozygous	_	_	_	_	_	_	_	_
9	pathogenic	_	_	_	_	_	_	_	_
10	variant	_	_	_	_	_	_	_	_
11	in	_	_	_	_	_	_	_	_
12	a	_	_	_	_	_	_	_	_
13	recessive	_	_	_	_	_	_	_	_
14	condition	_	_	_	_	_	_	_	_
15	,	_	_	_	_	_	_	_	_
16	the	_	_	_	_	_	_	_	_
17	gene	_	_	_	_	_	_	_	_
18	was	_	_	_	_	_	_	_	_
19	MEFV	_	_	_	_	_	_	_	_
20	.	_	_	_	_	_	_	_	_


1	If	_	_	_	_	_	_	_	_
2	we	_	_	_	_	_	_	_	_
3	had	_	_	_	_	_	_	_	_
4	included	_	_	_	_	_	_	_	_
5	heterozygous	_	_	_	_	_	_	_	_
6	carriers	_	_	_	_	_	_	_	_
7	of	_	_	_	_	_	_	_	_
8	a	_	_	_	_	_	_	_	_
9	MEFV	_	_	_	_	_	_	_	_
10	pathogenic	_	_	_	_	_	_	_	_
11	variant	_	_	_	_	_	_	_	_
12	,	_	_	_	_	_	_	_	_
13	the	_	_	_	_	_	_	_	_
14	genetic	_	_	_	_	_	_	_	_
15	diagnosis	_	_	_	_	_	_	_	_
16	yield	_	_	_	_	_	_	_	_
17	would	_	_	_	_	_	_	_	_
18	have	_	_	_	_	_	_	_	_
19	improved	_	_	_	_	_	_	_	_
20	up	_	_	_	_	_	_	_	_
21	to	_	_	_	_	_	_	_	_
22	10	_	_	_	_	_	_	_	_
23	%	_	_	_	_	_	_	_	_
24	(	_	_	_	_	_	_	_	_
25	Figure	_	_	_	_	_	_	_	_
26	2	_	_	_	_	_	_	_	_
27	)	_	_	_	_	_	_	_	_
28	.	_	_	_	_	_	_	_	_


1	In	_	_	_	_	_	_	_	_
2	an	_	_	_	_	_	_	_	_
3	attempt	_	_	_	_	_	_	_	_
4	to	_	_	_	_	_	_	_	_
5	find	_	_	_	_	_	_	_	_
6	a	_	_	_	_	_	_	_	_
7	cause	_	_	_	_	_	_	_	_
8	that	_	_	_	_	_	_	_	_
9	could	_	_	_	_	_	_	_	_
10	explain	_	_	_	_	_	_	_	_
11	the	_	_	_	_	_	_	_	_
12	low	_	_	_	_	_	_	_	_
13	rate	_	_	_	_	_	_	_	_
14	of	_	_	_	_	_	_	_	_
15	genetic	_	_	_	_	_	_	_	_
16	confirmation	_	_	_	_	_	_	_	_
17	using	_	_	_	_	_	_	_	_
18	panels	_	_	_	_	_	_	_	_
19	in	_	_	_	_	_	_	_	_
20	the	_	_	_	_	_	_	_	_
21	patients	_	_	_	_	_	_	_	_
22	referred	_	_	_	_	_	_	_	_
23	to	_	_	_	_	_	_	_	_
24	us	_	_	_	_	_	_	_	_
25	,	_	_	_	_	_	_	_	_
26	we	_	_	_	_	_	_	_	_
27	wondered	_	_	_	_	_	_	_	_
28	whether	_	_	_	_	_	_	_	_
29	validation	_	_	_	_	_	_	_	_
30	of	_	_	_	_	_	_	_	_
31	the	_	_	_	_	_	_	_	_
32	request	_	_	_	_	_	_	_	_
33	by	_	_	_	_	_	_	_	_
34	a	_	_	_	_	_	_	_	_
35	specialized	_	_	_	_	_	_	_	_
36	reference	_	_	_	_	_	_	_	_
37	center	_	_	_	_	_	_	_	_
38	could	_	_	_	_	_	_	_	_
39	improve	_	_	_	_	_	_	_	_
40	this	_	_	_	_	_	_	_	_
41	performance	_	_	_	_	_	_	_	_
42	.	_	_	_	_	_	_	_	_


1	The	_	_	_	_	_	_	_	_
2	success	_	_	_	_	_	_	_	_
3	of	_	_	_	_	_	_	_	_
4	the	_	_	_	_	_	_	_	_
5	NGS	_	_	_	_	_	_	_	_
6	approach	_	_	_	_	_	_	_	_
7	was	_	_	_	_	_	_	_	_
8	suggested	_	_	_	_	_	_	_	_
9	to	_	_	_	_	_	_	_	_
10	rely	_	_	_	_	_	_	_	_
11	on	_	_	_	_	_	_	_	_
12	its	_	_	_	_	_	_	_	_
13	use	_	_	_	_	_	_	_	_
14	in	_	_	_	_	_	_	_	_
15	the	_	_	_	_	_	_	_	_
16	context	_	_	_	_	_	_	_	_
17	of	_	_	_	_	_	_	_	_
18	a	_	_	_	_	_	_	_	_
19	highly	_	_	_	_	_	_	_	_
20	specialized	_	_	_	_	_	_	_	_
21	clinical	_	_	_	_	_	_	_	_
22	service	_	_	_	_	_	_	_	_
23	for	_	_	_	_	_	_	_	_
24	patients	_	_	_	_	_	_	_	_
25	with	_	_	_	_	_	_	_	_
26	AIDs	_	_	_	_	_	_	_	_
27	.	_	_	_	_	_	_	_	_


1	National	_	_	_	_	_	_	_	_
2	reference	_	_	_	_	_	_	_	_
3	centers	_	_	_	_	_	_	_	_
4	and	_	_	_	_	_	_	_	_
5	networks	_	_	_	_	_	_	_	_
6	cover	_	_	_	_	_	_	_	_
7	all	_	_	_	_	_	_	_	_
8	the	_	_	_	_	_	_	_	_
9	expertise	_	_	_	_	_	_	_	_
10	necessary	_	_	_	_	_	_	_	_
11	for	_	_	_	_	_	_	_	_
12	patient	_	_	_	_	_	_	_	_
13	care	_	_	_	_	_	_	_	_
14	and	_	_	_	_	_	_	_	_
15	operational	_	_	_	_	_	_	_	_
16	management	_	_	_	_	_	_	_	_
17	and	_	_	_	_	_	_	_	_
18	efficiency	_	_	_	_	_	_	_	_
19	.	_	_	_	_	_	_	_	_


1	We	_	_	_	_	_	_	_	_
2	established	_	_	_	_	_	_	_	_
3	a	_	_	_	_	_	_	_	_
4	pre-requisite	_	_	_	_	_	_	_	_
5	for	_	_	_	_	_	_	_	_
6	a	_	_	_	_	_	_	_	_
7	systematic	_	_	_	_	_	_	_	_
8	evaluation	_	_	_	_	_	_	_	_
9	of	_	_	_	_	_	_	_	_
10	undifferentiated	_	_	_	_	_	_	_	_
11	AIDs	_	_	_	_	_	_	_	_
12	patients	_	_	_	_	_	_	_	_
13	by	_	_	_	_	_	_	_	_
14	clinicians	_	_	_	_	_	_	_	_
15	from	_	_	_	_	_	_	_	_
16	reference	_	_	_	_	_	_	_	_
17	centers	_	_	_	_	_	_	_	_
18	.	_	_	_	_	_	_	_	_


1	It	_	_	_	_	_	_	_	_
2	is	_	_	_	_	_	_	_	_
3	possible	_	_	_	_	_	_	_	_
4	that	_	_	_	_	_	_	_	_
5	many	_	_	_	_	_	_	_	_
6	doctors	_	_	_	_	_	_	_	_
7	from	_	_	_	_	_	_	_	_
8	non-reference	_	_	_	_	_	_	_	_
9	centers	_	_	_	_	_	_	_	_
10	could	_	_	_	_	_	_	_	_
11	not	_	_	_	_	_	_	_	_
12	find	_	_	_	_	_	_	_	_
13	the	_	_	_	_	_	_	_	_
14	time	_	_	_	_	_	_	_	_
15	to	_	_	_	_	_	_	_	_
16	present	_	_	_	_	_	_	_	_
17	their	_	_	_	_	_	_	_	_
18	patients	_	_	_	_	_	_	_	_
19	to	_	_	_	_	_	_	_	_
20	MSM	_	_	_	_	_	_	_	_
21	.	_	_	_	_	_	_	_	_


1	This	_	_	_	_	_	_	_	_
2	certainly	_	_	_	_	_	_	_	_
3	accounts	_	_	_	_	_	_	_	_
4	for	_	_	_	_	_	_	_	_
5	the	_	_	_	_	_	_	_	_
6	decrease	_	_	_	_	_	_	_	_
7	in	_	_	_	_	_	_	_	_
8	the	_	_	_	_	_	_	_	_
9	proportion	_	_	_	_	_	_	_	_
10	of	_	_	_	_	_	_	_	_
11	patients	_	_	_	_	_	_	_	_
12	referred	_	_	_	_	_	_	_	_
13	by	_	_	_	_	_	_	_	_
14	the	_	_	_	_	_	_	_	_
15	non-reference	_	_	_	_	_	_	_	_
16	centers	_	_	_	_	_	_	_	_
17	.	_	_	_	_	_	_	_	_


1	However	_	_	_	_	_	_	_	_
2	,	_	_	_	_	_	_	_	_
3	our	_	_	_	_	_	_	_	_
4	study	_	_	_	_	_	_	_	_
5	showed	_	_	_	_	_	_	_	_
6	that	_	_	_	_	_	_	_	_
7	this	_	_	_	_	_	_	_	_
8	strategy	_	_	_	_	_	_	_	_
9	resulted	_	_	_	_	_	_	_	_
10	in	_	_	_	_	_	_	_	_
11	a	_	_	_	_	_	_	_	_
12	better	_	_	_	_	_	_	_	_
13	clinical	_	_	_	_	_	_	_	_
14	filter	_	_	_	_	_	_	_	_
15	for	_	_	_	_	_	_	_	_
16	ordering	_	_	_	_	_	_	_	_
17	genetic	_	_	_	_	_	_	_	_
18	tests	_	_	_	_	_	_	_	_
19	and	_	_	_	_	_	_	_	_
20	almost	_	_	_	_	_	_	_	_
21	doubled	_	_	_	_	_	_	_	_
22	the	_	_	_	_	_	_	_	_
23	performance	_	_	_	_	_	_	_	_
24	of	_	_	_	_	_	_	_	_
25	our	_	_	_	_	_	_	_	_
26	NGS	_	_	_	_	_	_	_	_
27	strategy	_	_	_	_	_	_	_	_
28	.	_	_	_	_	_	_	_	_


1	Also	_	_	_	_	_	_	_	_
2	,	_	_	_	_	_	_	_	_
3	our	_	_	_	_	_	_	_	_
4	reference	_	_	_	_	_	_	_	_
5	center	_	_	_	_	_	_	_	_
6	recently	_	_	_	_	_	_	_	_
7	offered	_	_	_	_	_	_	_	_
8	a	_	_	_	_	_	_	_	_
9	diagnostic	_	_	_	_	_	_	_	_
10	checklist	_	_	_	_	_	_	_	_
11	to	_	_	_	_	_	_	_	_
12	guide	_	_	_	_	_	_	_	_
13	practitioners	_	_	_	_	_	_	_	_
14	who	_	_	_	_	_	_	_	_
15	may	_	_	_	_	_	_	_	_
16	suspect	_	_	_	_	_	_	_	_
17	an	_	_	_	_	_	_	_	_
18	AID	_	_	_	_	_	_	_	_
19	for	_	_	_	_	_	_	_	_
20	ordering	_	_	_	_	_	_	_	_
21	genetic	_	_	_	_	_	_	_	_
22	tests	_	_	_	_	_	_	_	_
23	.	_	_	_	_	_	_	_	_


1	In	_	_	_	_	_	_	_	_
2	our	_	_	_	_	_	_	_	_
3	patients	_	_	_	_	_	_	_	_
4	with	_	_	_	_	_	_	_	_
5	a	_	_	_	_	_	_	_	_
6	conclusive	_	_	_	_	_	_	_	_
7	diagnosis	_	_	_	_	_	_	_	_
8	of	_	_	_	_	_	_	_	_
9	AID	_	_	_	_	_	_	_	_
10	,	_	_	_	_	_	_	_	_
11	the	_	_	_	_	_	_	_	_
12	main	_	_	_	_	_	_	_	_
13	features	_	_	_	_	_	_	_	_
14	identified	_	_	_	_	_	_	_	_
15	were	_	_	_	_	_	_	_	_
16	mucocutaneous	_	_	_	_	_	_	_	_
17	,	_	_	_	_	_	_	_	_
18	articular	_	_	_	_	_	_	_	_
19	,	_	_	_	_	_	_	_	_
20	and	_	_	_	_	_	_	_	_
21	gastro-intestinal	_	_	_	_	_	_	_	_
22	.	_	_	_	_	_	_	_	_


1	This	_	_	_	_	_	_	_	_
2	result	_	_	_	_	_	_	_	_
3	reflects	_	_	_	_	_	_	_	_
4	daily	_	_	_	_	_	_	_	_
5	practice	_	_	_	_	_	_	_	_
6	because	_	_	_	_	_	_	_	_
7	the	_	_	_	_	_	_	_	_
8	cutaneous/mucosal	_	_	_	_	_	_	_	_
9	,	_	_	_	_	_	_	_	_
10	digestive	_	_	_	_	_	_	_	_
11	tract	_	_	_	_	_	_	_	_
12	,	_	_	_	_	_	_	_	_
13	and	_	_	_	_	_	_	_	_
14	musculoskeletal	_	_	_	_	_	_	_	_
15	systems	_	_	_	_	_	_	_	_
16	are	_	_	_	_	_	_	_	_
17	the	_	_	_	_	_	_	_	_
18	three	_	_	_	_	_	_	_	_
19	most	_	_	_	_	_	_	_	_
20	common	_	_	_	_	_	_	_	_
21	systems	_	_	_	_	_	_	_	_
22	involved	_	_	_	_	_	_	_	_
23	in	_	_	_	_	_	_	_	_
24	AIDs	_	_	_	_	_	_	_	_
25	.	_	_	_	_	_	_	_	_


1	We	_	_	_	_	_	_	_	_
2	cannot	_	_	_	_	_	_	_	_
3	rule	_	_	_	_	_	_	_	_
4	out	_	_	_	_	_	_	_	_
5	a	_	_	_	_	_	_	_	_
6	relative	_	_	_	_	_	_	_	_
7	underestimation	_	_	_	_	_	_	_	_
8	of	_	_	_	_	_	_	_	_
9	the	_	_	_	_	_	_	_	_
10	potential	_	_	_	_	_	_	_	_
11	of	_	_	_	_	_	_	_	_
12	NGS	_	_	_	_	_	_	_	_
13	panels	_	_	_	_	_	_	_	_
14	for	_	_	_	_	_	_	_	_
15	AIDs	_	_	_	_	_	_	_	_
16	in	_	_	_	_	_	_	_	_
17	general	_	_	_	_	_	_	_	_
18	.	_	_	_	_	_	_	_	_


1	Indeed	_	_	_	_	_	_	_	_
2	,	_	_	_	_	_	_	_	_
3	because	_	_	_	_	_	_	_	_
4	of	_	_	_	_	_	_	_	_
5	our	_	_	_	_	_	_	_	_
6	study	_	_	_	_	_	_	_	_
7	design	_	_	_	_	_	_	_	_
8	,	_	_	_	_	_	_	_	_
9	some	_	_	_	_	_	_	_	_
10	of	_	_	_	_	_	_	_	_
11	the	_	_	_	_	_	_	_	_
12	patients	_	_	_	_	_	_	_	_
13	or	_	_	_	_	_	_	_	_
14	their	_	_	_	_	_	_	_	_
15	relatives	_	_	_	_	_	_	_	_
16	were	_	_	_	_	_	_	_	_
17	not	_	_	_	_	_	_	_	_
18	available	_	_	_	_	_	_	_	_
19	for	_	_	_	_	_	_	_	_
20	NGS	_	_	_	_	_	_	_	_
21	or	_	_	_	_	_	_	_	_
22	segregation	_	_	_	_	_	_	_	_
23	analysis	_	_	_	_	_	_	_	_
24	.	_	_	_	_	_	_	_	_


1	However	_	_	_	_	_	_	_	_
2	,	_	_	_	_	_	_	_	_
3	our	_	_	_	_	_	_	_	_
4	aim	_	_	_	_	_	_	_	_
5	was	_	_	_	_	_	_	_	_
6	not	_	_	_	_	_	_	_	_
7	to	_	_	_	_	_	_	_	_
8	evaluate	_	_	_	_	_	_	_	_
9	the	_	_	_	_	_	_	_	_
10	exact	_	_	_	_	_	_	_	_
11	performance	_	_	_	_	_	_	_	_
12	of	_	_	_	_	_	_	_	_
13	NGS	_	_	_	_	_	_	_	_
14	but	_	_	_	_	_	_	_	_
15	to	_	_	_	_	_	_	_	_
16	find	_	_	_	_	_	_	_	_
17	ways	_	_	_	_	_	_	_	_
18	to	_	_	_	_	_	_	_	_
19	improve	_	_	_	_	_	_	_	_
20	it	_	_	_	_	_	_	_	_
21	.	_	_	_	_	_	_	_	_


1	In	_	_	_	_	_	_	_	_
2	addition	_	_	_	_	_	_	_	_
3	to	_	_	_	_	_	_	_	_
4	the	_	_	_	_	_	_	_	_
5	successful	_	_	_	_	_	_	_	_
6	clinical	_	_	_	_	_	_	_	_
7	option	_	_	_	_	_	_	_	_
8	we	_	_	_	_	_	_	_	_
9	demonstrated	_	_	_	_	_	_	_	_
10	here	_	_	_	_	_	_	_	_
11	,	_	_	_	_	_	_	_	_
12	it	_	_	_	_	_	_	_	_
13	is	_	_	_	_	_	_	_	_
14	easy	_	_	_	_	_	_	_	_
15	to	_	_	_	_	_	_	_	_
16	predict	_	_	_	_	_	_	_	_
17	the	_	_	_	_	_	_	_	_
18	upcoming	_	_	_	_	_	_	_	_
19	discovery	_	_	_	_	_	_	_	_
20	of	_	_	_	_	_	_	_	_
21	new	_	_	_	_	_	_	_	_
22	genes	_	_	_	_	_	_	_	_
23	or	_	_	_	_	_	_	_	_
24	molecular	_	_	_	_	_	_	_	_
25	mechanisms	_	_	_	_	_	_	_	_
26	involved	_	_	_	_	_	_	_	_
27	in	_	_	_	_	_	_	_	_
28	AIDs	_	_	_	_	_	_	_	_
29	that	_	_	_	_	_	_	_	_
30	will	_	_	_	_	_	_	_	_
31	continue	_	_	_	_	_	_	_	_
32	to	_	_	_	_	_	_	_	_
33	revolutionize	_	_	_	_	_	_	_	_
34	our	_	_	_	_	_	_	_	_
35	routine	_	_	_	_	_	_	_	_
36	genetic	_	_	_	_	_	_	_	_
37	diagnosis	_	_	_	_	_	_	_	_
38	.	_	_	_	_	_	_	_	_


1	Recent	_	_	_	_	_	_	_	_
2	inputs	_	_	_	_	_	_	_	_
3	of	_	_	_	_	_	_	_	_
4	the	_	_	_	_	_	_	_	_
5	literature	_	_	_	_	_	_	_	_
6	advocate	_	_	_	_	_	_	_	_
7	closer	_	_	_	_	_	_	_	_
8	interactions	_	_	_	_	_	_	_	_
9	between	_	_	_	_	_	_	_	_
10	clinicians	_	_	_	_	_	_	_	_
11	and	_	_	_	_	_	_	_	_
12	geneticists	_	_	_	_	_	_	_	_
13	in	_	_	_	_	_	_	_	_
14	the	_	_	_	_	_	_	_	_
15	era	_	_	_	_	_	_	_	_
16	of	_	_	_	_	_	_	_	_
17	whole-genome	_	_	_	_	_	_	_	_
18	sequencing	_	_	_	_	_	_	_	_
19	.	_	_	_	_	_	_	_	_


1	Among	_	_	_	_	_	_	_	_
2	them	_	_	_	_	_	_	_	_
3	are	_	_	_	_	_	_	_	_
4	the	_	_	_	_	_	_	_	_
5	identification	_	_	_	_	_	_	_	_
6	of	_	_	_	_	_	_	_	_
7	genetic	_	_	_	_	_	_	_	_
8	modifiers	_	_	_	_	_	_	_	_
9	,	_	_	_	_	_	_	_	_
10	affecting	_	_	_	_	_	_	_	_
11	the	_	_	_	_	_	_	_	_
12	penetrance	_	_	_	_	_	_	_	_
13	of	_	_	_	_	_	_	_	_
14	homozygous	_	_	_	_	_	_	_	_
15	pathogenic	_	_	_	_	_	_	_	_
16	MVK	_	_	_	_	_	_	_	_
17	:	_	_	_	_	_	_	_	_
18	p.	_	_	_	_	_	_	_	_
19	(	_	_	_	_	_	_	_	_
20	Val377Ile	_	_	_	_	_	_	_	_
21	)	_	_	_	_	_	_	_	_
22	variant	_	_	_	_	_	_	_	_
23	;	_	_	_	_	_	_	_	_
24	the	_	_	_	_	_	_	_	_
25	lack	_	_	_	_	_	_	_	_
26	of	_	_	_	_	_	_	_	_
27	detection	_	_	_	_	_	_	_	_
28	of	_	_	_	_	_	_	_	_
29	pathogenic	_	_	_	_	_	_	_	_
30	variants	_	_	_	_	_	_	_	_
31	in	_	_	_	_	_	_	_	_
32	patients	_	_	_	_	_	_	_	_
33	with	_	_	_	_	_	_	_	_
34	a	_	_	_	_	_	_	_	_
35	clear	_	_	_	_	_	_	_	_
36	given	_	_	_	_	_	_	_	_
37	phenotype	_	_	_	_	_	_	_	_
38	,	_	_	_	_	_	_	_	_
39	such	_	_	_	_	_	_	_	_
40	as	_	_	_	_	_	_	_	_
41	pathogenic	_	_	_	_	_	_	_	_
42	canonical	_	_	_	_	_	_	_	_
43	splice	_	_	_	_	_	_	_	_
44	site	_	_	_	_	_	_	_	_
45	variants	_	_	_	_	_	_	_	_
46	not	_	_	_	_	_	_	_	_
47	covered	_	_	_	_	_	_	_	_
48	by	_	_	_	_	_	_	_	_
49	Sanger	_	_	_	_	_	_	_	_
50	and	_	_	_	_	_	_	_	_
51	panel	_	_	_	_	_	_	_	_
52	approaches	_	_	_	_	_	_	_	_
53	(	_	_	_	_	_	_	_	_
54	e.	_	_	_	_	_	_	_	_
55	g.	_	_	_	_	_	_	_	_
56	,	_	_	_	_	_	_	_	_
57	ADA2	_	_	_	_	_	_	_	_
58	:	_	_	_	_	_	_	_	_
59	c.	_	_	_	_	_	_	_	_
60	-47+2T>C	_	_	_	_	_	_	_	_
61	)	_	_	_	_	_	_	_	_
62	;	_	_	_	_	_	_	_	_
63	or	_	_	_	_	_	_	_	_
64	large	_	_	_	_	_	_	_	_
65	chromosomal	_	_	_	_	_	_	_	_
66	rearrangements	_	_	_	_	_	_	_	_
67	,	_	_	_	_	_	_	_	_
68	encompassing	_	_	_	_	_	_	_	_
69	several	_	_	_	_	_	_	_	_
70	genes	_	_	_	_	_	_	_	_
71	in	_	_	_	_	_	_	_	_
72	patients	_	_	_	_	_	_	_	_
73	with	_	_	_	_	_	_	_	_
74	complex	_	_	_	_	_	_	_	_
75	phenotypes	_	_	_	_	_	_	_	_
76	.	_	_	_	_	_	_	_	_


1	In	_	_	_	_	_	_	_	_
2	those	_	_	_	_	_	_	_	_
3	circumstances	_	_	_	_	_	_	_	_
4	,	_	_	_	_	_	_	_	_
5	an	_	_	_	_	_	_	_	_
6	MSM	_	_	_	_	_	_	_	_
7	could	_	_	_	_	_	_	_	_
8	help	_	_	_	_	_	_	_	_
9	find	_	_	_	_	_	_	_	_
10	the	_	_	_	_	_	_	_	_
11	best	_	_	_	_	_	_	_	_
12	appropriate	_	_	_	_	_	_	_	_
13	strategy	_	_	_	_	_	_	_	_
14	in	_	_	_	_	_	_	_	_
15	accordance	_	_	_	_	_	_	_	_
16	with	_	_	_	_	_	_	_	_
17	the	_	_	_	_	_	_	_	_
18	patient	_	_	_	_	_	_	_	_
19	â€™s	_	_	_	_	_	_	_	_
20	phenotype	_	_	_	_	_	_	_	_
21	.	_	_	_	_	_	_	_	_


1	The	_	_	_	_	_	_	_	_
2	role	_	_	_	_	_	_	_	_
3	of	_	_	_	_	_	_	_	_
4	the	_	_	_	_	_	_	_	_
5	reference	_	_	_	_	_	_	_	_
6	centers	_	_	_	_	_	_	_	_
7	is	_	_	_	_	_	_	_	_
8	to	_	_	_	_	_	_	_	_
9	determine	_	_	_	_	_	_	_	_
10	whether	_	_	_	_	_	_	_	_
11	or	_	_	_	_	_	_	_	_
12	not	_	_	_	_	_	_	_	_
13	the	_	_	_	_	_	_	_	_
14	clinical/anamnesis/genealogical	_	_	_	_	_	_	_	_
15	tree	_	_	_	_	_	_	_	_
16	is	_	_	_	_	_	_	_	_
17	compatible	_	_	_	_	_	_	_	_
18	with	_	_	_	_	_	_	_	_
19	a	_	_	_	_	_	_	_	_
20	known	_	_	_	_	_	_	_	_
21	AID	_	_	_	_	_	_	_	_
22	.	_	_	_	_	_	_	_	_


1	If	_	_	_	_	_	_	_	_
2	compatibility	_	_	_	_	_	_	_	_
3	does	_	_	_	_	_	_	_	_
4	not	_	_	_	_	_	_	_	_
5	seem	_	_	_	_	_	_	_	_
6	to	_	_	_	_	_	_	_	_
7	be	_	_	_	_	_	_	_	_
8	the	_	_	_	_	_	_	_	_
9	case	_	_	_	_	_	_	_	_
10	,	_	_	_	_	_	_	_	_
11	the	_	_	_	_	_	_	_	_
12	role	_	_	_	_	_	_	_	_
13	is	_	_	_	_	_	_	_	_
14	to	_	_	_	_	_	_	_	_
15	evaluate	_	_	_	_	_	_	_	_
16	the	_	_	_	_	_	_	_	_
17	potential	_	_	_	_	_	_	_	_
18	added	_	_	_	_	_	_	_	_
19	value	_	_	_	_	_	_	_	_
20	to	_	_	_	_	_	_	_	_
21	perform	_	_	_	_	_	_	_	_
22	the	_	_	_	_	_	_	_	_
23	NGS	_	_	_	_	_	_	_	_
24	.	_	_	_	_	_	_	_	_


1	If	_	_	_	_	_	_	_	_
2	this	_	_	_	_	_	_	_	_
3	value	_	_	_	_	_	_	_	_
4	appears	_	_	_	_	_	_	_	_
5	to	_	_	_	_	_	_	_	_
6	be	_	_	_	_	_	_	_	_
7	low	_	_	_	_	_	_	_	_
8	,	_	_	_	_	_	_	_	_
9	the	_	_	_	_	_	_	_	_
10	reference	_	_	_	_	_	_	_	_
11	center	_	_	_	_	_	_	_	_
12	recommends	_	_	_	_	_	_	_	_
13	that	_	_	_	_	_	_	_	_
14	no	_	_	_	_	_	_	_	_
15	NGS	_	_	_	_	_	_	_	_
16	be	_	_	_	_	_	_	_	_
17	conducted	_	_	_	_	_	_	_	_
18	in	_	_	_	_	_	_	_	_
19	discussion	_	_	_	_	_	_	_	_
20	with	_	_	_	_	_	_	_	_
21	geneticists	_	_	_	_	_	_	_	_
22	.	_	_	_	_	_	_	_	_


1	Thus	_	_	_	_	_	_	_	_
2	,	_	_	_	_	_	_	_	_
3	this	_	_	_	_	_	_	_	_
4	discussion	_	_	_	_	_	_	_	_
5	decreases	_	_	_	_	_	_	_	_
6	the	_	_	_	_	_	_	_	_
7	number	_	_	_	_	_	_	_	_
8	of	_	_	_	_	_	_	_	_
9	individuals	_	_	_	_	_	_	_	_
10	whose	_	_	_	_	_	_	_	_
11	phenotype	_	_	_	_	_	_	_	_
12	is	_	_	_	_	_	_	_	_
13	not	_	_	_	_	_	_	_	_
14	typically	_	_	_	_	_	_	_	_
15	enough	_	_	_	_	_	_	_	_
16	.	_	_	_	_	_	_	_	_

